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Background: The development of a two-bladed spreadable video-
mediastinoscope in 1992 allowed increased exposure and bimanual
dissection of mediastinal structures. Concurrent with technical
progress in mediastinoscopy, neoadjuvant treatment of stage III lung
cancer was introduced, and accuracy of pretreatment mediastinal
staging became a topic at issue. In this setting, development of a
videomediastinoscopic technique for complete mediastinal lymph-
adenectomy was the obvious thing to do.
Methods: Video-assisted mediastinoscopic lymphadenectomy (VAMLA)
dissection is guided by anatomical landmarks, very similar to open
lymphadenectomy. It includes en bloc resection of the right and
central compartments and dissection and lymphadenectomy of the
left-sided compartments. In a preliminary case-control study of 40
patients, VAMLA technique was standardized and evaluated against
open lymphadenectomy. A second study investigated 130 patients
with resectable lung cancer and radiographically normal mediasti-
num who underwent VAMLA and consecutive lung resection with
mediastinal reexploration.
Results: VAMLA harvested significantly more nodes than open
lymphadenectomy. With a mean duration of 54 minutes and a
complication rate of 4.6%, VAMLA appeared applicable to clinical
routine. We noted a sensitivity of 93.8%, a specificity of 100%, and
a false-negative rate of 0.9%.
Conclusions: In our experience, VAMLA is a feasible method of
mediastinal staging. Its accuracy and radicality can equal open
lymphadenectomy. However, VAMLA is minimally invasive and
therefore pretherapeutically available. Its advantages might be of
interest with neoadjuvant strategies, trials, involved field radiation,
video-assisted thoroscopic lobectomy, and left-sided tumors.
Key Words: Lung cancer, Mediastinal lymph nodes, Mediastinal
staging, Mediastinoscopy, Videomediastinoscopy, VAMLA.
(J Thorac Oncol. 2007;2: 367–369)
INDICATIONS
Video-assisted mediastinoscopic lymphadenectomy
(VAMLA) is a mediastinoscopic dissection technique de-
signed for maximum accuracy with a radicality equal to open
lymphadenectomy.1 VAMLA is minimally invasive and
therefore pretherapeutically available.
VAMLA might be of interest whenever high accuracy
or complete mediastinal dissection is mandatory in the stag-
ing of thoracic malignancies.2 Pretherapy indications are
neoadjuvant strategies for minor mediastinal involvement or
minimalized field radiation for functionally inoperable pa-
tients. VAMLA is a useful complement to mediastinal dis-
section at resection, especially with video-assisted thoro-
scopic (VATS) lobectomy and left-sided tumors. VAMLA
can reduce repeat mediastinoscopies after neoadjuvant treat-
ment for a subset of completely dissected patients with
microscopic disease. We encourage the use of VAMLA in
studies of lung cancer multimodality therapy and evaluation
of new prognostic factors.
TECHNIQUE
The spreadable Linder-Dahan videomediastinoscope
(Figure 1), which allows increased exposure and bimanual
dissection of mediastinal structures, is a prerequisite for
VAMLA.1–4 VAMLA dissection includes the en bloc resec-
tion of the subcarinal, right paratracheal, right tracheobron-
chial, and pretracheal compartments and dissection and
lymphadenectomy of the left-sided tracheobronchial and
paratracheal compartments.1–4 Details of VAMLA dissection
technique are shown in Figure 2.
RESULTS
In a preliminary series of 40 patients,1 we standard-
ized the VAMLA technique and compared the number of
removed lymph nodes with a matched open lymphadenec-
tomy cohort. VAMLA harvested significantly more nodes
(20.7 versus 14.3; p  0.0001). Leschber et al.4 focused on
dissected stations and demonstrated complete dissection
rates of 96%, 92%, 100%, and 100% for the stations 2R,
4R, 7, and 4L. They suggested VAMLA in combination
with VATS lobectomy.
Our second study2 investigated 130 patients with re-
sectable lung cancer and radiographically normal mediasti-
num who underwent VAMLA and consecutive lung resection
with mediastinal reexploration. The mean duration of
VAMLA was 54 minutes. Six complications (4.6%) were
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observed. Mediastinal involvement (13.1%) was detected by
VAMLA in 15 patients and by thoracotomy in two patients.
The sensitivity of VAMLA was 93.8%, the specificity was
100%, and the false-negative rate was 0.9%.
Within our internal quality management, we reviewed
85 patients who underwent endoscopic ultrasonography/fine-
needle aspiration (EUS-FNA) and VAMLA to assess EUS-
FNA accuracy and to redefine our pathway for pretherapy
mediastinal staging. We found the sensitivity of EUS-FNA to
be 90.1% for bulky disease, 88.9% for enlarged mediastinal
nodes, and 46.2% in a radiographically normal mediastinum.
Our clinical experience, with more than 300 VAMLA
procedures to date, has helped to shape a specific profile of
limitations, complications, and contraindications.2 We have
found difficult working conditions, sometimes associated
with incomplete dissections, in patients with calcified or
silicotic nodes, mediastinal scarring or fibrosis, intrathoracic
struma, contracted cervical spine, and extreme obesity.
VAMLA is helpful to manage minor intraoperative bleeding
from bronchial arteries and azygos or thyroid veins, but it is
impossible to achieve definitive control of major bleeding.
The most common complication is temporary left recurrent
nerve paralysis; other complications included pleural effu-
sion, chylothorax, and mediastinitis. We see contraindica-
tions in patients with coagulopathies, severe cerebrovascular
disease, and bulky disease or extranodal tumor growth.
IMPLICATIONS FOR CLINICAL PRACTICE
VAMLA is a feasible method of mediastinal staging with
accuracy comparable with that of open lymphadenectomy.1,2
Advantages of VAMLA are the minimally invasive approach,
the pretherapeutic availability, additional options such as medi-
astinoscopic sonography,5 extended mediastinoscopy,6 and, par-
ticularly in left-sided tumors and VATS lobectomy, improved
access to contralateral mediastinal nodes.4
Thus, VAMLA provides a highly accurate answer to
questions concerning pretherapeutic mediastinal staging of
FIGURE 1. The Linder-Dahan videomediastinoscope is a
cross-breed of a conventional mediastinoscope and a spread-
able laryngoscope. The blades are spread open up to 32
mm by turning a screw (a). Lowering the lower blade by
turning the spacer (b) allows an additional 20 mm of oper-
ating field. The tip of the upper blade (c) is designed to
keep surrounding structures, e.g., fatty tissue or the pulmo-
nary artery, out of the operating field. It accommodates
light, optic, continuous suction, and irrigation.
FIGURE 2. Video-assisted mediastinoscopic lymphadenec-
tomy dissection is guided by anatomical landmarks very sim-
ilar to open lymphadenectomy. (a) First, bifurcation and pul-
monary artery are exposed. The tip of the mediastinoscope
is placed below the artery, and the subcarinal compartment
is excised en bloc, following the medial borders of both
main bronchi and the anterior esophagus wall. (b) Then, the
mediastinoscope is retracted to the innominate artery. The
pleura parietalis and vena cava superior are exposed, and
the pre- and right paratracheal fat pads are removed en bloc
down to the azygos vein and the right main bronchus. (c)
Finally, the left recurrent nerve is visualized, and the pretra-
cheal fascia is divided between the nerve and the left border
of the airway. The left paratracheal and tracheobronchial
adipose tissue is carefully dissected, and all visible lymph
nodes removed. (Reprinted from Witte et al.2 with permis-
sion from the Society of Thoracic Surgeons.)
TABLE 1. Video-Assisted Mediastinoscopic
Lymphadenectomy Feasibility and Accuracy Data
Resected Nodes
More than Open
Lymphadenectomy (p < 0.0001)
Feasibility Mean duration 54 min
Complication rate 4.6%
Accuracy Sensitivity 93.8%
Specificity 100%
False-negative rate 0.9%
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lung cancer.7 However, depending on oncologic and surgical
strategies, this answer will not always have implications, and
sometimes questions might not be asked.
Keeping in mind the wide range of individual or insti-
tutional attitudes toward multimodal treatment of stage III
disease, desired staging accuracy for scientific or clinical
purposes, and necessary extent of intraoperative lymphade-
nectomy, we suggest the following indications:
To improve pretherapeutic mediastinal staging for defined
oncologic strategies: neoadjuvant strategy for stage III lung
cancer, especially when considered for minor mediastinal
involvement, and the smallest possible radiation field in
functionally compromised, nonresectable patients (in-
volved field radiation).
To improve mediastinal staging in trials investigating new
prognostic factors or therapies.
To improve mediastinal radicality in specific surgical set-
tings: VATS lobectomy and left-sided tumors.
To avoid repeat mediastinoscopies after complete VAMLA
resection of microscopic mediastinal disease and neoadju-
vant treatment.
VAMLA should not be the first step in invasive medi-
astinal staging in patients with markedly enlarged mediastinal
nodes or bulky disease. In these cases, FNA techniques
provide excellent accuracy, and videomediastinoscopy is re-
served for assessment of negative FNA results or restaging
after neoadjuvant treatment.
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